Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Madhu Nagaraj, Rafla Hassan, Jeannette Green, Glenn S. Kroog, Karen Rodriguez Lorenc, Christian Hampp, Qiufei Ma, Brian G.M. Durie (2024). Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-210376.
Article37 days agoComparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María‐Victoria Mateos, Borja Puertas Martínez, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksaç, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Paul Spin, Nicolle Bonar, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Christian Hampp, Brian G.M. Durie (2024). Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200679.
Article37 days agoComparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
Shaji Kumar, Sundar Jagannath, Katja Weisel, Laura Rosiñol Dachs, Meletios A Dimopoulos, David S. Siegel, Jorge Monge, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María‐Victoria Mateos, Borja Puertas Martínez, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksaç, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Paul Spin, Nicolle Bonar, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Christian Hampp, Brian G.M. Durie (2024). Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200679.
Article37 days agoFinal analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Xiaomei Shu, Chuang Li, Meletios A Dimopoulos (2023). Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. , 7(14), DOI: https://doi.org/10.1182/bloodadvances.2023010026.
Article37 days agoCarfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning
Meletios A Dimopoulos, Ola Landgren, David S. Siegel, Sebastian Grosicki, Albert Oriol, Rani Najdi, Chuang Li, Khalid Mezzi, Natalie Shu, Hang Quach (2023). Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning. , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-190726.
Article37 days ago